About

Advanced Medical Projects is a biotechnology company with presence in Madrid and Boston, interested in rare diseases caused by DNA stability, oxidative stress and low telomerase activity, also in syndromes caused by accelerated aging where the previous factors are proved very important. Most of these diseases are pediatric, like dyskeratosis congenita or ataxia telangiectasia, but some are present in adults, like idiopathic pulmonary fibrosis. We follow a “bottom-up” approach to research, so we study many different aspects of aging, telomerase function and chromosome stability to understand basic biological and physiological areas. Once we understand basic principles, we look for mechanisms able to act over some particular biochemical and genetic pathway.
AMP is the first company to develop a patented family of human peptides as a therapeutic product candidates able to increase Telomerase activity in senescent cells, increase DNA repair and also increase cell response against oxidative stress. Most of drugs are mostly developed as PLGA encapsulated principles to be administered as i.v. once or twice per month. Telomerase is a molecular complex of very difficult biomedical manipulation; its role is to maintain the length of telomeres, which are special DNA sequences located at the end of chromosomes to protect them from degradation.
Working on oxidative stress, we have developed a new drug against Fragile X Syndrome, that already passed Clinical Phase III. Patients treated with the drug, versus those treated with the placebo, have shown very clear improvement in cognitive and learning capacities and functions. We plan to bring this drug to patients by the end of 2015.
As cells divide in normal life, telomeres become shorter and shorter, and eventually the cell becomes senescent, does not repair its DNA and suffers more and more from oxidative stress. Abnormal telomere shortening means abnormal aging and also increase of mutations that may cause cancer. On the other hand, oxidative stress is a key factor in fibrosis processes.
Our patented GSE24-2 peptides have already demonstrated in vitro potential in several diseases, including cancer, Dyskeratosis Congenita, Werner Syndrome, Idiopathic Pulmonary Fibrosis, etc. GSE24-2 is currently in preclinical studies, in animal models, and based on the results generated so far we hope to reach very soon studies in human patients. Currently, we are also developing new administration platforms for these peptides, able to guarantee safety and correct dosage.
Finally, the company has also developed a complete line of cosmetics products using some of its patented molecules. These products are marketed worldwide and we reinvest 100% of all profits in the development of these pediatric drugs.